Biopharma Deal
Benchmarks

Section 2

Therapeutic Area Economics at Phase 2

Phase 2 is the canonical benchmark stage for biopharma deal economics — it represents the point at which clinical proof-of-concept exists but significant development risk remains. Across therapeutic areas, median upfronts at Phase 2 range from $200M (hematology, n=5) to $1.2B (metabolic, n=11), a 6x spread that reflects fundamental differences in market size, competitive dynamics, and clinical risk profiles.

Metabolic/obesity leads on absolute value with a $1.2B median upfront (n=11, P25-P75: $175M-$1.65B), though the wide interquartile range signals a bimodal market: validated GLP-1 follow-ons command transformative premiums, while earlier-stage mechanisms with unproven efficacy trade at conventional levels. Gastroenterology — historically a mid-tier therapeutic area — shows a surprising $725M median (n=10, P25-P75: $109M-$3.2B), driven by a small number of high-value IBD and liver disease transactions that distort the median given the limited sample size.

Immunology Phase 2 upfronts reached $400M median (n=15, P25-P75: $98M-$1.25B) — 1.4x the oncology median of $282M (n=236, P25-P75: $198M-$386M). The immunology premium is driven by anti-TL1A mechanism validation following Merck's $10.8B Prometheus acquisition and expanding CAR-T autoimmune programs. However, the critical difference is sample quality: oncology's n=236 produces a tight interquartile range ($188M spread), while immunology's n=15 generates a $1.15B range — meaning the median is directional, not definitive.

Neurology Phase 2 upfronts sit at $226M median (n=18, P25-P75: $125M-$510M), reflecting the long development timelines and binary clinical risk characteristic of CNS indications. Cardiovascular shows $310M (n=11, P25-P75: $205M-$860M), buoyed by renewed interest in PCSK9 and cardiac inflammation targets.

Section 4

Deal Structure Composition

Licensing is the dominant deal structure, accounting for 732 of 1,600+ transactions (31%). Acquisitions represent 530 deals (23%), followed by collaborations at 469 (20%), co-developments at 294 (13%), and options at 289 (12%). This distribution has shifted meaningfully over the sample period: licensing grew from 58 deals in 2020 to 190 in 2024 (3.3x), while acquisitions grew more modestly from 73 to 110 (1.5x).

The 2026 YTD data (n=190) shows licensing at 101 deals — already 53% of the total Q1 volume and 72% of full-year 2025 licensing volume (140 deals) achieved in a single quarter. Acquisitions are tracking at 36, suggesting a potential full-year pace of ~144, roughly in line with 2024. The structural shift is unmistakable: pharma is deploying capital through licensing at an accelerating rate while acquisition activity has plateaued.

The drivers are structural and durable. Patent cliffs through 2028 force faster pipeline rebuilds, and licensing is faster than M&A — no shareholder vote, no antitrust review, no integration risk. The IRA's Medicare negotiation provisions have also made US-centric deal economics less predictable, increasing the appeal of territory-split structures where the biotech retains US rights and licenses ex-US at a 30-40% discount to global value.

Section 6

Q1 2026 Market Themes

Three structural forces dominated biopharma dealmaking in the first quarter of 2026. These are not cyclical fluctuations — they represent durable shifts in how pharmaceutical companies build pipelines, source innovation, and allocate capital. Understanding these themes is essential for any BD team negotiating deals in the current environment.

Five of the top 20 pharmaceutical companies lost late-stage programs in the last six months, triggering an unprecedented wave of replacement transactions. In the first six weeks of 2026 alone, $9.2B in replacement deals were announced — transactions where the acquirer's own pipeline failure was a primary catalyst. Average deal size is up 76% versus 2025, reflecting the urgency and competitive intensity of these replacement searches.

The pattern is stark. Novo Nordisk's EVOKE trial failure accelerated their move into next-generation delivery platforms, culminating in the Aspect Biosystems partnership. AbbVie wrote down $3.5B on emraclidine following Phase 2 futility, then executed $6.8B in neurology deals within 90 days — a pace that suggests replacement targets were already identified before the failure readout. Bristol Myers Squibb's Camzyos nHCM program failure preceded the $1.5B Orbital Therapeutics acquisition by just weeks.

For biotech sellers, pipeline failures at large pharma create the single most favorable negotiating environment possible. The buyer has board-level pressure to fill a gap, a defined therapeutic area need, and allocated capital. Biotechs with Phase 2 assets in impacted therapeutic areas should expect inbound interest within days of a major failure readout — and should negotiate accordingly.

Chinese biotech out-licensing has gone from a niche deal category to the single largest source of global licensing volume. Total deal value from Chinese biotechs reached $136B in 2025 (+162% YoY) and $52B in the first eight weeks of 2026 alone — matching the entire 2024 total in under two months. This is not cost arbitrage: average China-originated deal size is $1.3B, up 76% versus 2025, reflecting genuine innovation premium.

The PD-1/VEGF bispecific class illustrates the dynamic perfectly: Pfizer licensed from 3SBio, BMS partnered with BioNTech-Biotheus, and Merck acquired rights from LaNova — three separate Western pharma companies licensing the same drug class from three different Chinese biotechs. Chinese biotechs now account for approximately 90% of global ADC out-licensing, a concentration that reflects Western pipelines being structurally thin in antibody-drug conjugates and bispecific antibodies.

The key transactions underscore the scale: AstraZeneca/CSPC ($18.5B), GSK/Hengrui ($12B+), BMS/BioNTech-Biotheus ($11.1B), and Pfizer/3SBio ($6B). Six of the top 10 pharma companies have now licensed at least one asset from a Chinese biotech in the last 12 months. ADCs and PD-1/VEGF bispecifics dominate the flow, but the trend is expanding into small molecules, degraders, and cell therapies.

Eli Lilly's $2.75B deal with Insilico Medicine (announced March 29, 2026) marks the moment AI drug discovery became a credible dealmaking category. The transaction included $115M upfront for oral therapeutics developed using Insilico's AI-powered Pharma.AI platform — validating that AI-discovered molecules can command institutional-scale deal economics, not just research collaboration fees.

The broader pipeline supports the trend: 28 drugs developed using AI tools are now in clinical or preclinical stages, with nearly half at clinical stage. The Lilly/Insilico deal is significant not for the AI label, but because the deal terms — $115M upfront, $2.75B total value — are consistent with Phase 1/2 licensing benchmarks for the relevant therapeutic areas. AI-discovered molecules are being priced on clinical merit, not on the novelty of their discovery methodology.

For BD teams, this has immediate practical implications. AI drug discovery companies are graduating from research collaboration partners (typical deal: $50-100M TDV, minimal upfront) to licensing partners commanding institutional-scale economics. Expect 3-5 additional AI-originated deals exceeding $1B TDV before year-end 2026, concentrated in oncology small molecules and metabolic targets where AI-driven structure prediction has the most validated track record.

Section 7

Modality Premiums

Radiopharmaceuticals overtook ADCs for the highest modality multiplier at 1.60x over small molecule baselines. The convergence of Novartis Pluvicto validation (>$1B annual sales within 18 months), constrained isotope supply, and platform acquisitions by BMS, Lilly, and AstraZeneca drove aggressive bidding for remaining independent radiopharmaceutical companies. At the oncology Phase 2 median of $282M (n=236), this implies a $451M upfront for a radiopharmaceutical asset at the same stage.

ADC premiums normalized to 1.45x from a ~1.70x peak during the 2023 Pfizer/Seagen cycle. At $282M baseline, this implies $409M for a Phase 2 ADC. Bispecific antibodies held at 1.35x ($381M implied), buoyed by teclistamab, epcoritamab, and glofitamab validation in hematologic malignancies. See our royalty rate benchmarks for modality-specific royalty analysis.

Interactive

Model Your Own Deal

Select your therapeutic area, phase, and modality to see live benchmarks from our database of 1,600+ verified transactions.